Buza Uchwepheshe: Okufanele Ukwazi Ngokuxilongwa Kwakho kwe-HER2 +
-Delile
- 1. Kusho ukuthini ngempela i-HER2-positive?
- 2. Ngabe ngizodinga ukuhlinzwa? Uma kunjalo, yiziphi izinketho zami?
- 3. Yiziphi izindlela zokwelashwa ezitholakalayo?
- 4. Ziyini izinhloso zokwelashwa?
- 5. Uyini umbono womdlavuza webele we-HER2?
- 6. Ingabe ikhona imiphumela engemihle yokwelashwa, futhi ngingayilawula kanjani?
- 7. Ngabe zikhona izinguquko endleleni yokuphila okufanele ngizenze ngemuva kokuxilongwa?
- 8. Iyini ingozi yami yokuphindaphinda komdlavuza webele we-HER2?
1. Kusho ukuthini ngempela i-HER2-positive?
I-HER2-positive imele i-human epidermal growth factor receptor 2. Amaseli emzimbeni ngokuvamile athola imiyalezo ezokhula futhi isabalale ivela kuma-receptors atholakala ngaphandle kweseli. Lawa ma-receptors azwela kuma-enzyme ahlukahlukene, noma izithunywa, ezikhiqizwa emzimbeni. Ama-receptors alawula amaseli ahlukahlukene futhi abatshele ukuthi benzeni (isb., Khula, usakaze, noma ufe).
Lawa ma-receptors nawo angaphandle kwamangqamuzana omdlavuza. Kepha, amangqamuzana omdlavuza angaba nama-receptors amaningi kakhulu kuneseli elijwayelekile. Le nombolo eyandisiwe, kanye nolunye ushintsho oluzungeze iseli lomdlavuza, ivumela ukuthi bathole imilayezo eminingi ezokhula futhi isabalale uma iqhathaniswa namaseli ajwayelekile, angenalo umdlavuza. Lawa ma-receptors siwabiza ngokuthi “ama-oncodrivers,” okusho ukuthi aqhuba umdlavuza ukuba ukhule.
Kulezi zimo, umdlavuza ungancika kakhulu kulawo ma-receptors ukuze aqhubeke nokukhula nokusabalala. Lapho lawa ma-receptors evinjelwe futhi engavunyelwe ukuthola imiyalezo, iseli alikwazi ukukhula noma ukusabalala.
Emdlavuzeni webele we-HER2-positive, inani lama-receptors atholakala ku-HER2 angaphandle kweseli likhulu kunalokho okuzoba kuseli elijwayelekile, elingenalo umdlavuza. Lokhu kusiza ukushayela umdlavuza ukuba ukhule futhi usabalale.
2. Ngabe ngizodinga ukuhlinzwa? Uma kunjalo, yiziphi izinketho zami?
Ithimba lakho le-oncology lizonquma ukuthi ngabe udinga ukuhlinzwa futhi lixoxe ngokuthi yiluphi uhlobo lokuhlinzwa olungcono kakhulu kuwe. Izici eziningi ezahlukahlukene ziya ekunqumeni ukuthi hlobo luni lokuhlinzwa okufanele lwenziwe nokuthi uzohlinzwa nini (kungaba ngaphambi noma ngemuva kokwelashwa okuhlelekile). Odokotela bakho bazoxoxa nawe ngokuningiliziwe ngezinketho zakho, futhi ngokuhlanganyela, ningafinyelela esinqumweni.
3. Yiziphi izindlela zokwelashwa ezitholakalayo?
Izinketho zokwelashwa zifaka ukwelashwa ngemisebe, ukuhlinzwa, ukwelashwa ngamakhemikhali kanye nokwelashwa kwe-endocrine. Uzokwazi nokuthola ukwelashwa okubhekiswe ngqo kuma-HER2 receptors.
Izici eziningi zinquma uhlobo nesikhathi sokwelashwa ozokuthola. Lokhu kufaka iminyaka yakho, ezinye izimo zempilo, isigaba somdlavuza, nezinto ozithandayo. Ithimba lakho le-oncology kufanele lixoxe ngazo zonke izindlela zokwelashwa ezitholakalayo ngecala lakho elithile.
4. Ziyini izinhloso zokwelashwa?
Izinhloso zokwelashwa zixhomeke esigabeni somdlavuza webele onaso lapho uxilongwa. Kulabo abanomdlavuza webele wesigaba 0 kuya ku-3, inhloso yokwelashwa ukwelapha umdlavuza nokuvikela ukuphindeka okuzayo.
Isigaba 4 somdlavuza webele sisho ukuthi umdlavuza usabalale wadlulela ngaphesheya kwesifuba kanye nama-lymph node wendawo. Kulesi sigaba, inhloso yokwelashwa ukulawula ukukhula komdlavuza nokuvikela noma yikuphi ukulimala komzimba noma ubuhlungu.
Ngeshwa, isigaba 4 somdlavuza webele asikwazi ukwelashwa. Kodwa ngokufika kwemithi emisha nemisha, kungenzeka ukuhlala esikhathini sesifo esizinzile isikhathi eside.
5. Uyini umbono womdlavuza webele we-HER2?
Umbono womdlavuza webele we-HER2-incike ezintweni ezimbalwa ezihlukile. Lokhu kufaka isigaba somdlavuza, amandla akho okubekezelela ukwelashwa, iminyaka yakho, nesimo sakho sempilo samanje.
Ukufika kwemithi eminingi emisha nephumelelayo ehlosiwe esebenza ngokubambisana nezinye izindlela zokwelapha kuyaqhubeka nokwenza ngcono umbono wabesifazane abanomdlavuza webele we-HER2.
6. Ingabe ikhona imiphumela engemihle yokwelashwa, futhi ngingayilawula kanjani?
Imiphumela emibi yokwelashwa izoncika ohlotsheni lokwelashwa odlula kulo. Ngokuvamile, iziguli zingakwazi ukubekezelela ama-antibody monoclonal asetshenziselwa ukukhomba kahle ama-HER2-positive receptors.
Eminye imiphumela emibi engaba khona ihlanganisa ukukhathala, ubuhlungu bamalunga, ikhanda elibuhlungu nokuqwasha. Iningi lale miphumela engemihle lincane kakhulu.
Imvamisa, ama-antibody monoclonal asetshenziselwa ukwelapha umdlavuza webele we-HER2 angadala ukuncipha kwemisipha yenhliziyo. Ithimba lakho le-oncology lizoxoxa nawe ngale ngozi futhi likuqaphe ngeso lokhozi nganoma yiziphi izimpawu zale nkinga engavamile.
7. Ngabe zikhona izinguquko endleleni yokuphila okufanele ngizenze ngemuva kokuxilongwa?
Ngokuvamile, kufanele ulandele indlela yokuphila enempilo ngemuva kokuxilongwa komdlavuza webele. Yeka ukubhema uma ubhema, nciphisa ukuphuza utshwala kwesinye isiphuzo noma ngaphansi ngosuku, futhi uvivinye umzimba ngokulingene nsuku zonke.
Kufanele futhi ulandele ukudla okunempilo okunezithelo, imifino, namaprotheni anamafutha amancane. Beka umkhawulo ekudleni ushukela ocwengekile kanye nokudla okunamafutha amaningi.
8. Iyini ingozi yami yokuphindaphinda komdlavuza webele we-HER2?
Ezigulini ezinomdlavuza webele we-HER2-positive (izigaba 0 kuya ku-3), iminyaka engu-10 yokuphinda ibuyele endaweni isukela kuma-79 kuye kuma-95 amaphesenti. Ububanzi buxhomeke esigabeni somdlavuza lapho kutholakala ukuxilongwa nohlobo lokuhlinzwa.
Kodwa-ke, kunezici eziningi ezingaba nomthelela engozini yakho yokuphindeka. Xoxa ngengozi yakho ngayinye neqembu lakho le-oncology.
Iseluleko esinikezwa nguHope Qamoos, umhlengikazi osebenza ngempilo yabesifazane. Ithemba lineminyaka engaphezu kwengu-15 yesipiliyoni lisebenza kwezempilo yabesifazane ne-oncology. Usebenzise umsebenzi wakhe wobungcweti esebenza nabaholi bemibono ebalulekile emkhakheni ezibhedlela zaseyunivesithi ezifana neStanford, Northwestern, neLoyola. Ngaphezu kwalokho, uHope usebenza nethimba elenza imikhakha eyahlukene ngenhloso yokwenza ngcono ukunakekelwa kwabesifazane abanomdlavuza eNigeria.